Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Oslo Bors  >  Photocure ASA    PHO   NO0010000045

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Oslo Bors
02/16/2017 02/17/2017 02/20/2017 02/21/2017 02/22/2017 Date
39.4(c) 37.6(c) 36.2(c) 37.8(c) 37.5(c) Last
31 646 126 991 39 205 70 773 40 538 Volume
-0.25% -4.57% -3.72% +4.42% -0.79% Change
More quotes
Financials ( NOK)
Sales 2017 155 M
EBIT 2017 4,38 M
Net income 2017 4,75 M
Finance 2017 97,8 M
Yield 2017 -
Sales 2018 198 M
EBIT 2018 45,6 M
Net income 2018 33,0 M
Finance 2018 164 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 24,71
EV / Sales2017 4,62x
EV / Sales2018 3,29x
Capitalization 815 M
More Financials
Company
Photocure ASA engages as a pharmaceutical company, which engages in the provision of photodynamic diagnosis and treatment.It operates through Commercial Franchise and Development Portfolio segments.The Commercial Franchise segment includes Hexvix/Cysview products and is broken down into own and... 
Sector
Pharmaceuticals
Calendar
04/27Shareholder meeting
More about the company
Surperformance© ratings of Photocure ASA
Trading Rating : Investor Rating :
More Ratings
Latest news on PHOTOCURE ASA
02/15 PHOTOCURE ASA : Results for fourth quarter and full year 2016
02/08 PHOTOCURE : A better future for patients with bladder cancer using advanced tech..
02/07 PHOTOCURE ASA : Presentation of the fourth quarter and full year 2016 results
02/03 PHOTOCURE : Completes Enrollment in US Market expansion study of Blue Light Flex..
01/23 PHOTOCURE ASA : Chairperson Bente-Lill Romøren not candidate for re-election
01/09 PHOTOCURE : to present at investor meetings in San Francisco
2016 PCI BIOTECH : PCIB - Disclosure of large shareholding
2016 PHOTOCURE : US registry shows that Blue Light Cystoscopy (BLC) with Cysview®/Hex..
2016 PHOTOCURE ASA : Share capital increase registered
2016 PHOTOCURE ASA : Blue Light Cystoscopy (BLC) with Cysview®/Hexvix® decreases the ..
More news
Sector news : Pharmaceuticals - NEC
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/22DJBAYER : Details Financing Plan for Monsanto Deal
02/22 EU regulators set to clear Dow, DuPont deal - sources
02/22 Covestro parent Bayer non-committal on any sale to industry peer
02/22DJBAYER : CEO Confident Monsanto Purchase Will Be Approved by End of Year -- Updat..
More sector news : Pharmaceuticals - NEC
Latest Tweets
2016Photocure : Repeat use of Blue Light Cystoscopy with Hexvix®/Cysview® shows e.. 
2016Photocure : Results for second quarter and first half year 2016  
2016BRIEF-Photocure: Cysview granted FDA approval of new prefilled syringe  
2016Photocure ASA : sponsored AUA webcast of the new AUA/SUO Non-muscle invasive ..
1
More tweets
Qtime:2
Advertisement
Chart PHOTOCURE ASA
Duration : Period :
Photocure ASA Technical Analysis Chart | PHO | NO0010000045 | 4-Traders
Full-screen chart
Technical analysis trends PHOTOCURE ASA
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 50,0  NOK
Spread / Average Target 32%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kjetil Hestdal President, Chief Executive Officer & Media Contact
Bente-Lill B. Romøren Chairman
Erik Dahl Chief Financial Officer & IR Contact
Inger Ferner Heglund Vice President-Research & Development
Xavier Denis Yon Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PHOTOCURE ASA-13.81%97
JOHNSON & JOHNSON3.86%325 539
ROCHE HOLDING LTD.5.98%212 000
PFIZER INC.3.51%204 018
NOVARTIS AG3.51%202 892
MERCK & CO., INC.11.23%180 537
More Results